Class substitution as an instrument of efficiency in the supply of medicines: Possibilities and limitations;Klassensubstitutie als doelmatigheidsinstrument in de geneesmiddelenvoorziening: Mogelijkheden en beperkingen

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 12, 2002, Pages 553-557

  De Smet, P A G M ^a   Van Der Kuy, A ^a   Bonsel, G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; COST CONTROL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; PRACTICE GUIDELINE; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COST ALLOCATION; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG MONITORING; HUMANS; PRESCRIPTIONS, DRUG; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0037160879     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Data en feiten over gencricke substitutie en therapeutische standaardisatie
2. Therapeutische standaardisatie
3. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease
4. Waardebepaling van geneesmiddelen: Werkzaamheid, toepasbaarheid, doeltreffendheid en doelmatigheid
5. Users' guides to the medical literature, XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect
6. Current perspectives on statins
7. Which beta-blocker?
8. Increased survival with beta-blockers: Importance of ancillary properties
9. Beta blockade after myocardial infarction: Systematic review and meta regression analysis
10. CARA CHECK-deelnemers krijgen farmaco-epidemiologische ondersteuning
11. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
12. COX-2-Selective NSAIDs: New and improved?
13. Increased thrombotic vascular events after change of statin
14. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
15. Evaluating the impact of reference-based pricing